Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

659
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
659
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Cancer Vaccines01:30

Cancer Vaccines

509
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
509
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

1.9K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
1.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Novel Selenium-Containing Small Molecule PD-L1 Inhibitors: Design, Synthesis, and Evaluation of the Antitumor Activity.

Journal of medicinal chemistry·2026
Same author

Research Progress and Clinical Translation Challenges of Small-Molecule Inhibitors Targeting PD-L1.

ChemMedChem·2026
Same author

Small-Molecule Inhibitors Targeting PD-1/PD-L1 in Colorectal Cancer: Mechanisms, Challenges, and Clinical Prospects.

ChemMedChem·2025
Same author

PD-L1-targeted novel molecule design: recent advances in immunomodulatory technologies and emerging insights in Cancer therapy.

Bioorganic chemistry·2025
Same author

Novel PD-L1 Small-Molecule Inhibitors Advancing Cancer Immunotherapy.

Anti-cancer agents in medicinal chemistry·2025
Same author

Comparative druggability of PD-1/PD-L1 inhibitors (A56, HD10): Cross-species differences in PD-L1 exposure and efficacy.

Bioorganic & medicinal chemistry·2025

相关实验视频

Updated: Sep 9, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

538

用PD-1抗体与药物结合物的癌症免疫疗法的创新及其抗瘤机制

Jianwei Wang1, Zeyu Chen2, Yanling Wu3

  • 1Lab of Drug Design and Synthesis, College of Pharmaceutical Science, Zhejiang University of Technology, Deqing 313299, China; Institute of Drug Development & Chemical Biology, Zhejiang University of Technology, Deqing 313299, China.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
|August 30, 2025
PubMed
概括

针对编程死亡-1 (PD-1) 的新型抗体-药物联合体 (ADC) 提供了癌症免疫治疗的双重方法. 这些PD-1ADCs可以逆转T细胞衰竭并直接向瘤输送细胞毒剂,增强免疫反应并克服抵抗力.

关键词:
抗体与药物的结合物癌症免疫疗法药物耐药性免疫检查点封锁美国

更多相关视频

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.8K
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.8K

相关实验视频

Last Updated: Sep 9, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

538
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.8K
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.8K

科学领域:

  • 癌症学
  • 免疫疗法
  • 药物开发

背景情况:

  • 抗体与药物结合剂 (ADC) 是癌症治疗的一个有希望的进步.
  • 编程死亡-1 (PD-1) 抑制剂是现代癌症免疫治疗的基石.
  • 对传统PD-1抑制剂的耐药性需要新的治疗策略.

研究的目的:

  • 引入和评估针对编程死亡-1 (PD-1) 的抗体药物联合体 (ADC).
  • 探索PD-1ADCs在逆转T细胞耗尽和传递细胞毒性有效载荷方面的双重机制.
  • 评估PD-1ADCs在克服对现有的免疫疗法的潜力.

主要方法:

  • 开发针对PD-1的新型抗体药物联合体 (ADC).
  • 在相关癌症模型中对PD-1 ADC进行临床前评估.
  • 分析瘤微环境中的免疫调节和直接细胞毒性作用.

主要成果:

  • PD-1 ADCs可以选择性地与PD-1表达细胞结合.
  • 这些药物在逆转T细胞耗尽和消除免疫抑制细胞方面具有潜力.
  • 这种双重机制增强了抗瘤免疫力,并解决了常规PD-1抑制剂所观察到的抗药性.

结论:

  • PD- 1 ADC 是一种具有双重作用机制的新型癌症免疫疗法.
  • 包括瘤抗原异质性和耐药性发展在内的挑战需要进一步调查.
  • 在ADC工程和有效载荷优化方面的未来创新对于临床成功至关重要.